Wen-Shin Lee, MD
Ophthalmology · Sun City West, AZNPI 1184068496
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Sight Sciences, Inc. at 49.3% of the total. Reporting peaked in 2022 at $2,456 and has fallen 62.1% since, to $931 in 2025.
Across 73 payments — averaging $65.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$2K
- Alcon$1K
- Glaukos Corporation$345
- AbbVie$227
- Aerie Pharmaceuticals, Inc.$148
- Carl Zeiss Meditec USA, Inc.$127
- plus $267 from 9 others
Across 4 payments — averaging $7552.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$30K
What the payments were for
- Speaking & faculty fees$2,00042%
- Food & beverage$2,81058%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 11 | $2,372 |
| Alcon | 37 | $1,323 |
| Glaukos Corporation | 7 | $345 |
| AbbVie(2 entities) | 4 | $227 |
| Aerie Pharmaceuticals, Inc. | 1 | $148 |
| Carl Zeiss Meditec USA, Inc. | 1 | $127 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $76 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| Thea Pharma Inc. | 1 | $23 |
| Ivantis, Inc | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Amgen | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $15 |
| NEW World Medical,inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$2,000
- iDoseTR$317
- Rhopressa$148
- XEN GLAUCOMA TREATMENT SYSTEM$131
- Clareon$130
- LUMERA 700$127
- Voyager DSLT$122
- AcrySof IQ PanOptix$117
How this compares
$4,810 in reported general payments places this provider in the 80th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 139 | $52,203 |
| LumiganBimatoprost | 52 | $26,020 |
| Prednisolone Acetate | 261 | $11,879 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 32 | $10,249 |
| AzoptBrinzolamide | 16 | $10,124 |
| RocklatanNetarsudil Mesylat/Latanoprost | 25 | $9,275 |
| VyzultaLatanoprostene Bunod | 26 | $8,645 |
| Methazolamide | 21 | $6,371 |
| Brinzolamide | 46 | $6,326 |
| Latanoprost | 802 | $6,269 |
| Brimonidine Tartrate | 295 | $4,718 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 213 | $3,976 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $3,967 |
| MoxifloxacinMoxifloxacin Hcl | 201 | $3,903 |
| TafluprostTafluprost/Pf | 19 | $3,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $148 | $61,479164 claims |
| AbbVieLumigan | $227 | $26,02052 claims |
| AlconSimbrinza, Azopt | $1,323 | $20,37448 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $61 | $8,64526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Sun City West
- Anne ZakiSun City West$518K
- Warren HillMesa$1.1M
- Mark BarakatScottsdale$794K
- Pravin DugelPhoenix$176K
- Derek KunimotoMesa$138K
- Shamil PatelGlendale$116K
- Yuri McKeeMesa$100K
- Nishi ShahPhoenix$92K
- Lisa MihoraPeoria$91K
- George ReissGlendale$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.